Literature DB >> 28984313

Human models of migraine - short-term pain for long-term gain.

Messoud Ashina1, Jakob Møller Hansen1, Bára Oladóttir Á Dunga1, Jes Olesen1.   

Abstract

Migraine is a complex disorder characterized by recurrent episodes of headache, and is one of the most prevalent and disabling neurological disorders. A key feature of migraine is that various factors can trigger an attack, and this phenomenon provides a unique opportunity to investigate disease mechanisms by experimentally inducing migraine attacks. In this Review, we summarize the existing experimental models of migraine in humans, including those that exploit nitric oxide, histamine, neuropeptide and prostaglandin signalling. We describe the development and use of these models in the discovery of molecular pathways that are responsible for initiation of migraine attacks. Combining experimental human models with advanced imaging techniques might help to identify biomarkers of migraine, and in the ongoing search for new and better migraine treatments, human models will have a key role in the discovery of future targets for more-specific and more-effective mechanism-based antimigraine drugs.

Entities:  

Mesh:

Year:  2017        PMID: 28984313     DOI: 10.1038/nrneurol.2017.137

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  164 in total

1.  "Monday head": an interesting occupational disorder.

Authors:  B W MCGUINNESS; E L HARRIS
Journal:  Br Med J       Date:  1961-09-16

Review 2.  The role of mast cells in migraine pathophysiology.

Authors:  Theoharis C Theoharides; Jill Donelan; Kristiana Kandere-Grzybowska; Aphrodite Konstantinidou
Journal:  Brain Res Brain Res Rev       Date:  2005-07

3.  A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.

Authors:  Louise Dickson; Ichiro Aramori; James McCulloch; John Sharkey; Keith Finlayson
Journal:  Neuropharmacology       Date:  2006-08-23       Impact factor: 5.250

4.  Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache.

Authors:  C Kruuse; E Frandsen; S Schifter; L L Thomsen; S Birk; J Olesen
Journal:  Cephalalgia       Date:  2004-07       Impact factor: 6.292

5.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

6.  The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects.

Authors:  Christina Kruuse; Lars Lykke Thomsen; Torsten Bjørn Jacobsen; Jes Olesen
Journal:  J Cereb Blood Flow Metab       Date:  2002-09       Impact factor: 6.200

7.  Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study.

Authors:  Faisal Mohammad Amin; Anders Hougaard; Stefano Magon; Mohammad Sohail Asghar; Nur Nabil Ahmad; Egill Rostrup; Till Sprenger; Messoud Ashina
Journal:  Neurology       Date:  2015-12-16       Impact factor: 9.910

8.  Premonitory symptoms in migraine: an electronic diary study.

Authors:  N J Giffin; L Ruggiero; R B Lipton; S D Silberstein; J F Tvedskov; J Olesen; J Altman; P J Goadsby; A Macrae
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

9.  Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers.

Authors:  L L Thomsen; H K Iversen; T A Brinck; J Olesen
Journal:  Cephalalgia       Date:  1993-12       Impact factor: 6.292

10.  Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks.

Authors:  Farooq Husain Maniyar; Till Sprenger; Teshamae Monteith; Christoph Schankin; Peter James Goadsby
Journal:  Brain       Date:  2013-11-25       Impact factor: 13.501

View more
  44 in total

Review 1.  Nitric oxide signalling in the brain and its control of bodily functions.

Authors:  Konstantina Chachlaki; Vincent Prevot
Journal:  Br J Pharmacol       Date:  2019-09-08       Impact factor: 8.739

Review 2.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

3.  Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling.

Authors:  Samaira Younis; Casper E Christensen; Mark B Vestergaard; Ulrich Lindberg; Daniel Tolnai; Olaf B Paulson; Henrik Bw Larsson; Anders Hougaard; Messoud Ashina
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

Review 4.  Targeted Nitric Oxide Synthase Inhibitors for Migraine.

Authors:  Amynah A Pradhan; Zachariah Bertels; Simon Akerman
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 5.  Migraine and the trigeminovascular system-40 years and counting.

Authors:  Messoud Ashina; Jakob Møller Hansen; Thien Phu Do; Agustin Melo-Carrillo; Rami Burstein; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2019-05-31       Impact factor: 44.182

6.  Aberrant activity within auditory network is associated with psychiatric comorbidities in interictal migraineurs without aura.

Authors:  Heng-Le Wei; Yu-Chen Chen; Yu-Sheng Yu; Xi Guo; Gang-Ping Zhou; Qing-Qing Zhou; Li-Jie Qu; Xindao Yin; Junrong Li; Hong Zhang
Journal:  Brain Imaging Behav       Date:  2021-01-21       Impact factor: 3.978

Review 7.  Targeting BKCa Channels in Migraine: Rationale and Perspectives.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Christian Gram; Cherie Amalie Waldorff Nielsen; Messoud Ashina
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 8.  The Role of Endothelin in the Pathophysiology of Migraine-a Systematic Review.

Authors:  Afrim Iljazi; Cenk Ayata; Messoud Ashina; Anders Hougaard
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

Review 9.  Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.

Authors:  Peer Tfelt-Hansen; Karl Messlinger
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

10.  Extra-Axial Inflammatory Signal in Parameninges in Migraine with Visual Aura.

Authors:  Nouchine Hadjikhani; Daniel S Albrecht; Caterina Mainero; Eri Ichijo; Noreen Ward; Cristina Granziera; Nicole R Zürcher; Oluwaseun Akeju; Guillaume Bonnier; Julie Price; Jacob M Hooker; Vitaly Napadow; Matthias Nahrendorf; Marco L Loggia; Michael A Moskowitz
Journal:  Ann Neurol       Date:  2020-04-22       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.